公 司 研 究 安迪苏（600299.SH）：业绩短期承 2024年3月29日 强烈推荐/维持 压，产能持续扩张巩固龙头地位 东 安迪苏 公司报告 兴 证 券 安迪苏发布2023年年报：全年实现营业收入为131.84亿元，YoY-9.26%，归 公司简介： 股 母净利润为0.52亿元，YoY-95.82%，EPS为0.02元。公司拟每10股派发现 安迪苏于 2006 年被中国蓝星集团收购，于 份 金红利0.6元（含税）。 2015 年借壳蓝星集团旗下的蓝星新材在 A 有 股上市。公司是全球第二大蛋氨酸生产商， 限 受到产品销售价格下滑，以及原材料、能源成本上升的双重挤压，公司业绩下 可同时提供固体蛋氨酸和液体蛋氨酸，是动 公 滑。从收入端看，2023年公司主要产品蛋氨酸市场均价同比2022年有所下滑， 物营养与健康行业的全球领军企业。 资料来源：公司公告、东兴证券研究所 司 导致公司营收小幅下滑。从利润端看，公司毛利率受到产品价格下滑的影响同 交易数据 比下滑7个百分点至21%，同时也受到资产减值和相关重组成本的影响（其中 证 券 主要由于 Commentry 固体蛋氨酸生产线，Innov’ia 的老旧工厂以 ...

Financial Performance - Net profit attributable to shareholders of the parent company for 2023 was RMB 52,165,518[4] - Cumulative distributable profit of the parent company as of December 31, 2023, was RMB 489,335,867[4] - Revenue in 2023 decreased by 9.26% year-on-year to RMB 13.18 billion, compared to RMB 14.53 billion in 2022[21] - Net profit attributable to shareholders dropped significantly by 95.82% to RMB 52.17 million in 2023, down from RMB 1.25 billion in 2022[21] - Basic earnings per share (EPS) fell by 95.65% to RMB 0.02 in 2023, compared to RMB 0.46 in 2022[22] - The weighted average return on equity (ROE) decreased by 8.36 percentage points to 0.35% in 2023[22] - Revenue for the period decreased by 9.26% to RMB 13,183,748,624 compared to the same period last year[54] - Gross profit margin for the nutrition and health industry decreased by 7 percentage points to 21%[56] - Functional products revenue decreased by 15% to RMB 8,807,341,566, with a gross margin reduction of 11 percentage points[56] - Special products revenue increased by 8% to RMB 3,593,810,639, but gross margin decreased by 4 percentage points[56] - Revenue in China increased by 11% to RMB 1,793,361,133, while other regions experienced declines[56] - Sales expenses increased by 5.49% to RMB 1,227,058,560, and management expenses rose by 9.84% to RMB 768,915,157[62] - R&D expenses increased by 18.17% to RMB 419,245,587, reflecting higher investment in innovation[54] - Net cash flow from operating activities increased significantly by 59.89% to RMB 2,764,212,304[54] - Total R&D investment in 2023 was RMB 518,242,447, accounting for 3.93% of total revenue, with 8.20% of R&D investment capitalized[63] - Operating cash flow in 2023 was RMB 2,764,212,304, a significant increase from RMB 1,728,821,216 in 2022, primarily due to strict cash and working capital management[67] - Total R&D expenditure in 2023 was RMB 518,242,447, accounting for 3.4% of net assets and 3.9% of operating revenue[84] - The total actual compensation paid to directors, supervisors, and senior management during the reporting period was RMB 52.44 million[153] - The company allocated a cash dividend of 404,967,092.22 yuan for 2022, representing 32.48% of the net profit attributable to shareholders[180] Profit Distribution and Dividends - Proposed cash dividend of RMB 0.6 per 10 shares, totaling RMB 160,914,076 (tax inclusive)[4] - The company plans to maintain the per-share distribution ratio and adjust the total distribution amount if the total share capital changes before the equity distribution record date[4] - The profit distribution plan is subject to approval at the 2023 Annual General Meeting of Shareholders[4] - The company's cash dividend policy mandates that at least 30% of the distributable profits be allocated as cash dividends when the company is profitable and has positive undistributed profits[180] Cash Flow and Working Capital Management - Operating cash flow increased by 59.89% to RMB 2.76 billion in 2023, driven by strict cash and working capital management[22] - Net cash flow from operating activities increased significantly by 59.89% to RMB 2,764,212,304[54] - Operating cash flow in 2023 was RMB 2,764,212,304, a significant increase from RMB 1,728,821,216 in 2022, primarily due to strict cash and working capital management[67] Non-Recurring Gains and Losses - Non-recurring gains and losses amounted to RMB 39.17 million in 2023, primarily due to government subsidies and asset disposal losses[25][26] Asset and Liability Management - Total assets increased slightly by 0.80% to RMB 21.51 billion at the end of 2023[21] - The company's net debt level decreased due to improved cash flow management[22] - Derivative financial assets increased by RMB 11.39 million, from RMB 4.88 million to RMB 16.28 million, impacting current profits by RMB 12.74 million[27] - Derivative financial liabilities decreased by RMB 354,904, from RMB 363,722 to RMB 8,818, impacting current profits by RMB -414,944[27] - Other equity instrument investments increased by RMB 15.15 million, from RMB 262.66 million to RMB 277.80 million[27] - Other non-current financial assets increased by RMB 33.15 million, from RMB 75.87 million to RMB 109.02 million, impacting current profits by RMB 27.84 million[27] - Total fair value changes amounted to RMB 60.05 million, with a total impact on current profits of RMB 40.16 million[27] - Overseas assets accounted for 55% of total assets, amounting to RMB 11,738,245,328, reflecting the company's global presence in animal nutrition additives[69] Environmental and Sustainability Goals - The company aims to reduce greenhouse gas emissions by 37% from 2020 to 2035 while maintaining business growth[30] - The company has already achieved its 2025 target of reducing greenhouse gas emissions, energy consumption, and water usage by 20% compared to 2025 levels[30] - The company has established a carbon reduction roadmap for 2050 in collaboration with a leading French sustainability consulting firm[30] - The company is committed to aligning its environmental goals with the Paris Agreement and the United Nations Framework Convention on Climate Change[30] - The company focuses on four key areas: reducing its own carbon footprint, contributing to reducing the carbon footprint across the value chain, ensuring responsible behavior towards employees and stakeholders, and enhancing governance and sustainability communication[30] - The company invested 23.38 million yuan in environmental protection during the reporting period[190] - The company's subsidiary, BlueStar Adisseo Nanjing Co., Ltd., maintained stable and compliant emissions of waste gas, wastewater, and noise in 2023[191] - The company's annual emissions of sulfur dioxide (SO2) were 3.65 tons, with an emission concentration of 1.148 mg/m³, well below the permitted limit of 200 mg/m³[192] - Nitrogen oxides (NOx) emissions totaled 134.47 tons annually, with an emission concentration of 53.04 mg/m³, within the permitted limits of 200-300 mg/m³[192] - Non-methane total hydrocarbon (NMHC) emissions were 4.149 tons annually, with an emission concentration of 1.25 mg/m³, significantly below the permitted limit of 80 mg/m³[193] - Chemical oxygen demand (COD) in wastewater was 44.11 tons annually, with a concentration of 122 mg/L, well below the permitted limit of 500 mg/L[194] - Ammonia nitrogen (NH3-N) in wastewater was 2.07 tons annually, with a concentration of 6.2 mg/L, significantly below the permitted limit of 45 mg/L[195] - Total suspended solids (SS) in wastewater were 10.96 tons annually, with a concentration of 31 mg/L, well below the permitted limit of 400 mg/L[195] - Five-day biochemical oxygen demand (BOD5) in wastewater was 12.84 tons annually, with a concentration of 36 mg/L, significantly below the permitted limit of 300 mg/L[195] - Total nitrogen (TN) in wastewater was 4.21 tons annually, with a concentration of 11.68 mg/L, well below the permitted limit of 70 mg/L[195] - Noise levels at the factory boundary were 59.98 dB(A) during the day and 52.29 dB(A) at night, both below the permitted limits of 65 dB(A) and 55 dB(A) respectively[195] - Hazardous waste generation in 2023 was 91,405.67 tons, with 91,002.95 tons processed internally and 402.73 tons transferred out[196] - The company completed the environmental online monitoring system for elevated flares in 2023 and connected it to the environmental protection department's platform[198] - The Nanjing factory's waste heat power generation project entered the testing phase in January 2024, aiming to utilize excess steam more effectively[198] - The acrylic acid wastewater treatment and reclaimed water reuse project is expected to start construction in 2024 and be operational by 2025, significantly reducing nitrogen oxide emissions and natural gas consumption[198] - The Nanjing factory passed the second round of clean production audit in February 2023, achieving the first level (international advanced level) of clean production[199] - The environmental protection acceptance of the Nanjing factory's second-phase project was completed on June 30, 2023[199] - The company completed two full-scale emergency drills for environmental incidents in 2023 and plans to continue drills in 2024 to enhance response capabilities[200] Production and Capacity Expansion - The company successfully increased annual production capacity by 80,000 tons through the expansion of European production platforms, including new production lines at Burgos and Les Roches factories[33] - The Nanjing liquid methionine plant (BANC2) reached a total capacity of 350,000 tons, making it one of the largest and most cost-competitive liquid methionine production platforms globally[33] - A new solid methionine plant with an annual capacity of 150,000 tons is planned in Quanzhou, expected to be operational by 2027[33] - The European production platform has successfully added 80,000 tons/year of liquid methionine capacity since Q3 2021, enhancing market competitiveness[36] - The Nanjing production platform's Phase II plant, with an annual capacity of 180,000 tons of liquid methionine, was completed and operational in September 2022[37] - A new solid methionine plant in Quanzhou, with an annual capacity of 150,000 tons, is planned to start production in 2027[37] - The company's market share of methionine increased from 24% to 27% between 2012 and 2017, maintaining a strong position in recent years[37] - The company decided not to restart the solid methionine production plant in Commentry in January 2024 to improve cost competitiveness[37] - The company holds approximately 20% of the global feed-grade Vitamin A production capacity[38] - Vitamin A prices dropped sharply from April 2022 due to a major producer's return to the market[38] - The company reduced Vitamin A production from Q4 2022 to optimize working capital management amid weak demand[38] - The company's global finished product transportation volume increased to 1.318 million tons in 2023, up from 1.098 million tons in 2022[80] - Anhui transported 103,000 tons of intermediate products using dedicated railway tank cars in 2023 for safety reasons[80] - The company's product portfolio includes methionine, vitamins, enzyme preparations, and other specialty products for animal feed applications[82] - The company's raw materials and finished products are stored in tanks and traditional warehouses, with unified management standards for both in-plant and off-plant warehouses[81] - The company's transportation strategy prioritizes safety, pollution reduction, and cost efficiency, with some routes adopting multimodal transportation to reduce carbon emissions[80] - The company's global market access planning enables precise technical specifications for each market, facilitating international business opportunities[82] - The company successfully obtained market access for its products in over 120 countries despite strict global trade measures and complex regulatory environments[83] - A new solid methionine plant in Quanzhou with a designed capacity of 150,000 tons/year is under construction, with an investment of RMB 170 million and expected completion in 2027[86][87] - The Nanjing plant's total capacity has been expanded to 350,000 tons/year after the completion of debottlenecking and liquid methionine phase II projects[88] - The company permanently closed the Commentry solid methionine production line in January 2024 to improve cost competitiveness[89] - Procurement costs for key raw materials decreased significantly: propylene (-17%), methanol (-14%), and sulfur (-43%)[90] - Energy procurement costs also decreased: natural gas (-33%) and electricity (-29%)[91] - The company uses derivative financial instruments to manage currency exchange rate risks, primarily through cash flow hedging[95][96] - Direct sales through the company's own network account for over 85% of total sales, with the remainder through distributors[94] Product Development and Innovation - A new product, DynOmik™, was launched in the US market in Q3 2023, aimed at improving milk production efficiency and sustainability[33] - The company's specialty products business achieved continuous revenue growth, driven by growth in aquatic and monogastric products, despite weak demand in the US and China dairy markets[33] - The company's joint venture, Kaidi Su, entered trial production and signed a strategic cooperation agreement with a leading Chinese feed producer for its innovative single-cell protein product[33] - The company launched a new technical service, Nestor, in Q3 2022, which has been widely adopted by key clients for feed formulation optimization[34] - DynOmik™, a new ruminant additive product, was fully launched in the North American market after its initial release in two US states in Q3 2023[34] - The company's R&D efforts are focused on five pillars: green production, new testing, multi-dimensional impact, innovation synergy, and digital empowerment[33] - The company's new R&D center in Lyon, operational in Q4 2023, integrates chemical, engineering, nutritional, and analytical capabilities[34] - The company launched DynOmik™ in the US in 2023, the first solution to increase milk production while reducing methane emissions in cows[51] - Adisseo's Rovabio Phyplus, the latest generation of phytase, improves overall nutritional efficiency, sustainability, and feed digestibility[51] - Adisseo established the "Sinochem Animal Nutrition Center Research Institute" in early 2023, strengthening collaborations with international labs, universities, and research institutions[50] - Adisseo's innovation lab focuses on disruptive technologies, products, and services to enhance customer productivity, sustainability, and animal health[46] - Adisseo's dual-pillar strategy includes maintaining leadership in the methionine market and accelerating the development of specialty product business[47] - The company's R&D investment in 2023 increased significantly compared to 2022, driven by increased project investments, with strategic collaborations established with universities and research institutions in Europe, China, and Singapore[66] - The company has 4 R&D centers and 2 experimental stations globally, focusing on areas such as biotechnology, chemical processes, and smart agriculture[84] - The company's long-term performance evaluation standards focus on sustainable shareholder value creation, including total shareholder return and profitability growth[176] - The company emphasizes the relationship between individual and organizational performance in determining executive compensation[177] Market and Competitive Position - The company's performance improved in the second half of 2023, with Q4 revenue reaching RMB 3.57 billion, the highest among all quarters[24] - Asset impairments and restructuring costs, particularly related to the closure of the Commentry solid methionine production line and Innov'ia plant, significantly impacted profitability[22] - The company's liquid methionine technology and cost leadership position it as one of the lowest-cost producers globally, with significant barriers to entry in the methionine market[72] - The animal feed additive industry is expected to grow due to global trends such as meat industrialization, population growth, and sustainable development, with emerging markets shifting towards protein-rich diets[72] - In 2023, the company's operating performance improved due to increased production, stable prices, reduced raw material and energy costs, and profit protection measures, despite challenges in the macroeconomic environment[72] - Anhui's global market leadership in methionine was consolidated in 2023 due to successful marketing and completion of expansion and debottlenecking projects in Europe and China[73] - Anhui decided to stop exporting solid methionine from France to the US and redirect limited products to other regions and countries[73] - Anhui permanently closed a solid methionine production line in Europe and adjusted liquid methionine production to mitigate the impact of global demand slowdown in 2023[73] - Anhui's vitamin business profitability stabilized in 2023 despite significant price pressure, benefiting from prudent production and price management[74] - The company faces competition from large, well-funded companies and new entrants, with strategies including cost control, process improvements, and capacity expansion in China and Europe[112] - Risks related to product development and technological advancements, particularly in methionine production, could impact competitiveness if competitors achieve breakthroughs first[114] Risk Management - The Russia-Ukraine conflict and Red Sea ship attacks have increased uncertainty, potentially leading to supply disruptions and higher costs for raw materials and energy[107] - The company faces risks from global macroeconomic fluctuations, serving over 4,200 customers in more than 110 countries[111] - Key raw materials such as acrylic, sulfur, methanol, ammonia, and natural gas are sourced from a limited number of suppliers, with potential risks from price volatility and supply disruptions[113] - The company is exposed to currency exchange risks due to operations primarily in euros and dollars, while financial statements are consolidated in RMB[116] - Compliance risks include potential violations of anti-corruption, antitrust, and international sanctions regulations, with extensive employee training programs in place to mitigate these risks[108] - Environmental regulations and potential changes in emission standards could require additional investments in sustainability and environmental facilities[109] - Tax and tariff risks include potential increases in effective tax rates due to changes in local tax laws and geopolitical tensions affecting import regulations[118] - Industrial risks include potential damage to individuals, property, or the environment, with some facilities classified as "highest level" chemical bases under EU directives[119] - Production involves hazardous chemicals and complex processes, with risks of leaks, emissions, and waste exceeding standards, potentially leading to civil, criminal, and financial liabilities[120] - Disease outbreaks (e.g., avian flu, African swine fever) and production accidents could significantly impact livestock numbers, consumer demand, and the company's financial performance[121] - Mismanagement of production plans, equipment failures, or overestimation of market demand could harm customer relationships and future sales[122] - Increasing cybersecurity threats, including phishing, hacking, and malware, pose risks to IT systems and data, potentially causing operational disruptions and reputational damage

蓝星安迪苏股份有限公司 董事会审计、风险及合规委员会 2023 年度履职报告 （2）向董事会提出聘请审计机构的建议 一．审计委员会基本情况介绍 2021 年 9 月，经第八届董事会第一次会议选举，第八届审计委员会成员原为：丁 远（主席），伍京皖和 Caroline Grégoire Sainte-Marie。其中，伍京皖先生自 2023 年 10 月 27 日起辞去公司董事（包括审计委员会成员）职务。经 2023 年 10 月 27 日召开的第 八届董事会第十三次会议及 2023 年 12 月 11 日召开的临时股东大会审议通过，孙岩峰 先生自 2023 年 12 月 11 日起任审计委员会成员。 审计委员会的组成与运行符合上海证券交易所的相关规定及《公司章程》和《审 计、风险及合规委员会实施细则》等制度的有关要求。 报告期内，审计委员会共召开 7 次会议，以下是具体内容： 召开日期 会议届次 会议议案 2023 年 2 月 15 日 第八届董事会审计、风 险及合规委员会第九次 会议 讨论了： 1. 2022 年业绩快报。 2023 年 3 月 28 日 第八届董事会审计、风 险及合规委员会第十次 会议 审议 ...

蓝星安迪苏股份有限公司 关于 2023 年度利润分配方案的公告 证券代码：600299 证券简称：安迪苏 公告编号：2024-006 监事会认为，公司的利润分配符合有关法律法规和《公司章程》的规定，充 分考虑了全体股东的利益，符合公司实际情况，未有损害公司和股东利益的情况 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要提示： 经毕马威华振会计师事务所（特殊普通合伙）审计，蓝星安迪苏股份有限公 司（简称"安迪苏"或"公司"）2023 年度合并层面实现归属于上市公司股东的 净利润为人民币 52,165,518 元，安迪苏母公司层面截至 2023 年 12 月 31 日累计可 供分配利润为人民币 489,335,867 元。 为了与全体股东分享公司业绩成果，同时促进公司进一步发展，董事会在充 分考虑公司实际运营情况的基础上，建议以实施权益分派股权登记日的总股本为 基础，向全体股东每 10股派发现金股利 0.6元人民币（含税），预计总额为人民币 160,914,076 元人民币（含税）。本年度公司现金分红比例为年度归属于上市公司 ...

蓝星安迪苏股份有限公司 内部控制审计报告 2023 年 12 月 31 日 KPMG Huazhen LLP 8th Floor, KPMG Tower Oriental Plaza 1 East Chang An Avenue Beijing 100738 China Telephone +86 (10) 8508 5000 +86 (10) 8518 5111 Fax Internet kpmg.com/cn 毕马威华振会计师事务所 (特殊普通合伙) 中国北京 东长安街1号 东方广场毕马威大楼8层 邮政编码 : 100738 电话 +86 (10) 8508 5000 传真 +86 (10) 8518 5111 网址 kpmg.com/cn 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部控制评价指 引》的规定，建立健全和有效实施内部控制，并评价其有效性是贵公司董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上，对财务报告内部控制的有效性发表审计意见,并 对注意到的非财务报告内部控制的重大缺陷进行披露。 KPMG Huazhen LLP, a People's Re ...

证券代码：600299 证券简称：安迪苏 公告编号：2024-008 蓝星安迪苏股份有限公司 2023 年年度主要经营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 蓝星安迪苏股份有限公司（以下简称"安迪苏"或"公司"）根据上海证券交 易所发布的《上市公司行业信息披露指引第十三号——化工》（2022年修订）和 《关于做好主板上市公司 2023 年年度报告披露工作的通知》的要求，现将公司 2023 年年度主要经营数据披露如下： 一、 主要产品销售情况 营业收入分产品情况 各类产品销售收入影响因素分析： 2023 年宏观市场环境格局振荡（包括市场环境的波动和不确定性、市场需 求缓慢恢复以及行业竞争加剧），公司的业绩主要受到功能性产品的销售价格下 滑以及原材料、能源成本上升的双重挤压。公司的经营表现（不包括一次性影 响）在 2023 年下半年逐渐改善。第四季度营业状况明显恢复，帮助 2023 年全 年的业绩实现微利。主要归功于： 单位:元 币种:人民币 主营业务分产品情况 分产品 营业收入 营业成本 毛利 率 营业收 入比 ...

关于独立性的说明 蓝星安迪苏股份有限公司 2023 年度独立董事述职报告 蓝星安迪苏股份有限公司 2023 年度独立董事述职报告 (丁远先生) 2023 年，作为蓝星安迪苏股份有限公司(以下简称"公司")独立董事，本人按照《公 司法》《上市公司独立董事管理办法》《上海证券交易所股票上市规则》以及《蓝星 安迪苏股份有限公司章程》《蓝星安迪苏股份有限公司独立董事工作制度》的规定和 要求，恪尽职守、勤勉尽责，详细了解公司运作情况，忠实履行独立董事职责，积极 出席相关会议，认真审议董事会及专门委员会各项议案，对相关事项发表独立意见， 充分发挥了独立董事的作用，维护了公司和股东，尤其是中小股东的利益。现将本人 作为公司独立董事在 2023 年度的工作情况报告如下。 一、独立董事的基本情况 丁远，生于 1969 年，法国籍。丁先生于 2000 年 5 月毕业于法国波尔多第四大学企 业管理学院，获管理学哲学博士学位。丁先生在财务会计、财务报表分析、企业管治 及合并与收购的教学及研究方面拥有逾二十年经验。自 1999 年 9 月至 2006 年 9 月，丁 先生在法国巴黎 HEC 管理学院担任会计与管理控制系的终身教授；自 ...

中化集团财务有限责任公司 风险评估报告 大华核字[2024]0011005080 号 大 华 会 计 师 事 务 所 （ 特 殊 普 通 合 伙 ） Da Hua Certified Public Accountants（SpecialGeneral Partnership） 大华会计师事务所（特殊普通合伙） 北京市海淀区西四环中路 16 号院 7 号楼 12 层 [100039] 电话：86 （10） 5835 0011 传真：86 （10） 5835 0006 www.dahua-cpa.com 中化集团财务有限责任公司 风险评估报告 （截止 2023 年 12 月 31 日） 目 录 页 次 一、 风险评估报告 1-2 二、 附件 1 风险评估说明 1-8 大华会计师事务所（特殊普通合伙） 北京市海淀区西四环中路 16 号院 7 号楼 12 层 [100039] 电话：86 （10） 5835 0011 传真：86 （10） 5835 0006 www.dahua-cpa.com 风 险 评 估 报 告 大华核字[2024] 0011005080 号 中化集团财务有限责任公司： 我们接受委托，审核了中化 ...

蓝星安迪苏股份有限公司 毕马威华振总所位于北京，注册地址为北京市东城区东长安街 1 号东方广场东 2 座办公楼 8 层。 毕马威华振的首席合伙人邹俊，中国国籍，具有中国注册会计师资格。 截至 2023 年 12 月 31 日，毕马威华振有合伙人 234 人，注册会计师 1,121 人， 其中签署过证券服务业务审计报告的注册会计师超过 260 人。 毕马威华振 2022 年经审计的业务收入总额超过人民币 41 亿元，其中审计业务 收入超过人民币 39 亿元（包括境内法定证券服务业务收入超过人民币 9 亿元，其他 证券服务业务收入超过人民币 10 亿元，证券服务业务收入共计超过人民币 19 亿元）。 毕马威华振 2022 年上市公司年报审计客户家数为 80 家，上市公司财务报表审 计收费总额约为人民币 4.9 亿元。这些上市公司主要行业涉及制造业，金融业，信 息传输、软件和信息技术服务业，电力、热力、燃气及水生产和供应业，交通运输、 仓储和邮政业，采矿业，房地产业，科学研究和技术服务业，批发和零售业，租赁 和商务服务业，水利、环境和公共设施管理业，以及文化、体育和娱乐业。毕马威 华振 2022 年本公司同行业上市 ...

经核查独立董事丁远先生、Caroline Grégoire Sainte-Marie 女士、臧恒昌先生 的任职经历以及签署的相关自查文件，上述人员未在公司担任除独立董事以外的 任何职务，也未在公司主要股东公司担任任何职务，与公司以及主要股东、实际 控制人之间不存在利害关系或其他可能妨碍其进行独立客观判断的关系，符合 《上市公司独立董事管理办法》《上海证券交易所股票上市规则（2023 年 8 月修 订）》《上海证券交易所上市公司自律监管指引第 1 号——规范运作（2023 年 8 月修订）》中关于独立董事独立性的相关要求。 蓝星安迪苏股份有限公司董事会 2024 年 3 月 28 日 根据证监会《上市公司独立董事管理办法》《上海证券交易所股票上市规则 （2023 年 8 月修订）》《上海证券交易所上市公司自律监管指引第 1 号——规范 运作（2023 年 12 月修订）》等要求，蓝星安迪苏股份有限公司（以下简称"公 司"）董事会，就公司 2023 年度任职独立董事丁远先生、Caroline Grégoire Sainte- Marie 女士、臧恒昌先生的独立性情况进行评估并出具如下专项意见： 蓝星安迪苏股份有限 ...